BackMoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics Target Price

Where could MLTX trade next? Consensus target price: $50.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.38

Average Target Price

$50.00339.4% upside

1 analysts in the last 4 months

High: $50 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-13H.C. Wainwright$50339.4% upsideOpen
2026-05-11H.C. Wainwright$45295.4% upsideOpen
2026-02-24Oppenheimer$35207.6% upsideOpen
2026-01-14Goldman Sachs$1012.1% downsideOpen
2026-01-09H.C. Wainwright$32181.2% upsideOpen
2026-01-09UBS$24110.9% upsideOpen
2026-01-08UBS$45295.4% upsideOpen
2025-11-21H.C. Wainwright$26128.5% upsideOpen
2025-11-06Oppenheimer$30163.6% upsideOpen
2025-11-03H.C. WainwrightRaghuram Selvaraju$30163.6% upsideOpen
2025-10-07Oppenheimer$25119.7% upsideOpen
2025-09-30Goldman Sachs$738.5% downsideOpen
2025-09-30NeedhamSerge Belanger$2075.7% upsideOpen
2025-09-30Guggenheim$2075.7% upsideOpen
2025-09-29Jefferies$829.7% downsideOpen
2025-09-29RBC Capital$1012.1% downsideOpen
2025-03-18RBC Capital$67488.8% upsideOpen
2024-07-01H.C. WainwrightRaghuram Selvaraju$100778.7% upsideOpen
2024-04-02Goldman SachsRichard Law$62444.8% upsideOpen
2023-08-31NeedhamSerge Belanger$76567.8% upsideOpen

MoonLake Immunotherapeutics (MLTX) FAQ

MoonLake Immunotherapeutics posts a target price of $50. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $50 for MLTX means covering analysts, on average, see the stock 339.4% upside of $11.38 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for MLTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; MoonLake Immunotherapeutics's other metric pages and overview cover the third.